ClinicalTrials.gg
RecruitingNCT07228468HOMEUpdated Jan 26, 2026

Home-Based Transcranial Direct Current Stimulation In Major Depressive Disorder (HOME)

An interventional study of transcranial direct current stimulation (tDCS) in Major Depressive Disorder (MDD), sponsored by King's College London. Recruiting at 6 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by King's College London · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
438
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Depressive Disorder, Major by King's College London — 2 open to participants now, 3 under way, none of them phase 3. Depressive Disorder, Major · King's College London.

Planned enrollment
Largest of 11
438 · median 60
Started
2025
the only one that year
No phase
8 of 15
2 open now
Registered
15th of 15
by date

Among the 15 studies in Depressive Disorder, Major by King's College London, this one has the largest planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 8 with no phase, and was the 15th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 15 studies in Depressive Disorder, Major by King's College London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Depressive Disorder, Major by King's College London, or all of them as a file.
02

Study summary

Depression is a prevalent and debilitating disorder. The most common treatments are antidepressant medications and talking therapies. However, for many individuals, these are not their treatment of choice. Furthermore, even following a full course of treatment with an antidepressant or talking therapy, over one third of patients continue to be unwell.

The novel brain stimulation treatment, transcranial direct current stimulation (tDCS), is a potential first-line treatment for major depression. The present research question is whether home-based tDCS is an effective treatment for major depression for adults with major depression.

Participants will be randomised to receive either a 10-week course of active tDCS treatment in addition to their standard care (Treatment as Usual), or to only receive Treatment as Usual. Participants will be followed up for 6-months after the start of the treatment began.

After the 6-month follow-up visit, all participants from both groups can choose to continue/start the tDCS treatment. There will be a final follow-up visit 3 months later (9 months from the original treatment start of the trial).

Read the detailed description

Current pharmacotherapy and psychotherapy treatments for major depressive disorder (MDD) often fall short in efficacy and patient satisfaction, highlighting a critical need for innovative, effective and acceptable treatment options. Transcranial direct current stimulation (tDCS) has emerged as a promising treatment, offering a non-invasive method to modulate brain activity and alleviate depressive symptoms that can be provided at home.

This trial builds on our work and aims to evaluate the effectiveness and cost-effectiveness of home-based tDCS as a treatment for MDD in the NHS. The trial is a multi-centre pragmatic RCT to evaluate the real-life clinical effectiveness and cost-effectiveness of tDCS combined with treatment as usual (TAU) as compared to TAU alone following a 10-week treatment period and at a 6-month follow up. Depressive symptoms will be measured by the clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS). We will further assess impact on self-report depressive symptoms, anxiety symptoms, remission, acceptability and quality of life. We will conduct in-depth process evaluation, economic evaluation, and implementation work to investigate operational challenges of integrating home-based tDCS into existing NHS care pathways and to inform scalability in primary care settings.

438 Participants will be aged 18 years or over, diagnosed with MDD with at least moderate severity of depressive symptoms and medication free or taking stable antidepressant medication or in psychotherapy for at least 6 weeks before enrolment. Participants will be randomly assigned in a 1:1 ratio to either TAU or TAU+tDCS.

Participants randomised to the TAU treatment arm will continue with standard care including psychotherapy and/or antidepressant medication, as decided by participant and treating clinician. Participants randomised to the tDCS treatment arm will use a tDCS device which is a headset with the anode positioned over left dorsolateral prefrontal cortex (DLPFC) and cathode over right DLPFC (EEG positions F3 and F4, respectively). Treatment protocol consists of 5 tDCS sessions per week for 3 weeks followed by 3 tDCS sessions per week for 7 weeks, for a total of 36 sessions in 10 weeks. tDCS stimulation is 2 mA for 30 minutes with gradual ramp up over 30 seconds at the start and end of each session.

The primary outcome is the difference in depressive symptoms between treatment arms at 10-week end of treatment as measured by MADRS and the key secondary outcome is the long term clinical effectiveness as measured by difference in depressive symptoms between treatment arms at 6-month follow up as measured by MADRS.

After the 6-month follow up, a 3-month extension follow up phase will give all participants the opportunity to use the tDCS device.

This research addresses an unmet need for new treatment options for MDD, thereby benefiting people with MDD, improving NHS care pathways, and expanding scientific knowledge.

03

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • transcranial direct current stimulation
  • tDCS
  • major depression
  • MDD
  • major depressive disorder
  • brain stimulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 years or over
  2. Current episode of depression based on , Fifth Edition (DSM-5) criteria (APA, 2013) for major depressive disorder (MDD) as assessed by structured clinical assessment, Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998)
  3. Having at least a moderate severity of depressive symptoms as measured by a score of at least 18 in MADRS
  4. Either not taking antidepressant medication or taking a stable dose of antidepressant medication for at least 6 weeks before enrolment.
  5. Either not currently in psychotherapy or in ongoing psychotherapy for at least 6 weeks before enrolment.
  6. Being under the care of GP
  7. Agreeable for GP to be regularly informed about study participation
  8. Able to provide written,

Exclusion criteria

Exclusion Criteria:

  1. Significant suicide risk as measured by answering 'yes' to questions 4, 5 or 6 on the Columbia Suicide Severity Rating Scale (C-SSRS) Screen (Posner et al., 2011)
  2. Primary comorbid psychiatric disorder (e.g. obsessive compulsive disorder) based on criteria as assessed in MINI
  3. Current daily use of medications that affect cortical excitability (e.g. benzodiazepines)
  4. Current illicit drug use or heavy alcohol use with high risk of alcohol use disorder as measured by a score of 8 or more in Alcohol use disorders identification test consumption (AUDIT C) (Khadjesari et al., 2017; NICE, 2023)
  5. History of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), or other brain stimulation
  6. History of esketamine / ketamine for treatment of depression
  7. History of psychosurgery for depression
  8. Having cognitive impairment (e.g. dementia)
  9. Current medical disorder or neurological disorder that may mimic mood disorder (e.g. hormonal disorder, unstable heart disease)
  10. Have any implant in the brain or neurocranial defect
  11. Have shrapnel or any ferromagnetic material in the head
  12. Have any active implantable medical device (e.g. pacemaker)
  13. If female and of , currently pregnant or planning to become pregnant during the study
  14. Concurrent enrolment in another interventional study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
438 participants (estimated)

Study arms

  • No intervention
    Treatment as usual (TAU)

    Treatment as usual will consist of standard care, such as psychotherapy and/or antidepressant medication or no treatment, as decided by participant and treating clinician.

  • Experimental
    transcranial direct current stimulation + treatment as usual (tDCS + TAU)

    In addition to receiving treatment as usual, participants randomized to receive tDCS will engage in a 10-week treatment protocol of active tDCS which participants will administer at home. Stimulation schedule is 5 sessions per week for 3 weeks followed by 3 sessions per week for 7 weeks, for a total of 36 sessions in 10 weeks. tDCS device is headset with bifrontal montage, anode at left dorsolateral prefrontal cortex (DLPFC) and cathode at right DLPFC (EEG positions F3 and F4, respectively). Stimulation is 2 mA for 30 minutes with a gradual ramp up over 30 seconds. Electrode area is 23 cm2.

    Device: transcranial direct current stimulation (tDCS)

Interventions

  • Devicetranscranial direct current stimulation (tDCS)

    Participants randomised to the tDCS treatment arm will use a tDCS device which is a headset with the anode positioned over left dorsolateral prefrontal cortex (DLPFC) and cathode over right DLPFC (EEG positions F3 and F4, respectively). Treatment protocol consists of 5 tDCS sessions per week for 3 weeks followed by 3 tDCS sessions per week for 7 weeks, for a total of 36 sessions in 10 weeks. tDCS stimulation is 2 mA for 30 minutes with gradual ramp up over 30 seconds at the start and end of each session.

06

What researchers measure

Primary outcomes

  1. Montgomery-Åsberg Depression Rating Scale (MADRS)

    To evaluate tDCS clinical effectiveness as the difference in depressive symptom severity at end of 10-week treatment period between two treatment arms: those receiving treatment as usual (TAU) alone and those receiving TAU plus tDCS

    Time frame: 10 weeks

Secondary outcomes

  1. Montgomery-Åsberg Depression Rating Scale (MADRS)

    To evaluate tDCS clinical effectiveness as the difference in depressive symptom severity at end of 6 month follow-up period between two treatment arms: those receiving treatment as usual (TAU) alone and those receiving TAU plus tDCS

    Time frame: 6 months

  2. Hamilton Depression Rating Scale (HDRS)

    To evaluate tDCS clinical effectiveness as the difference in depressive symptom severity at end of 10-week treatment period between two treatment arms: those receiving treatment as usual (TAU) alone and those receiving TAU plus tDCS

    Time frame: 10 weeks

  3. Hamilton Anxiety Rating Scale (HAMA)

    To evaluate tDCS clinical effectiveness as the difference in anxiety symptom severity at end of 10-week treatment period between two treatment arms: those receiving treatment as usual (TAU) alone and those receiving TAU plus tDCS

    Time frame: 10 weeks

  4. Montgomery-Åsberg Depression Rating Scale-Self Report (MADRS-S)

    To evaluate tDCS clinical effectiveness as the difference in depressive symptom severity at end of 10-week treatment period between two treatment arms: those receiving treatment as usual (TAU) alone and those receiving TAU plus tDCS

    Time frame: 10 weeks

  5. Hamilton Depression Rating Scale (HDRS)

    To evaluate tDCS clinical effectiveness as the difference in depressive symptom severity at end of the 6 month follow-up period between two treatment arms: those receiving treatment as usual (TAU) alone and those receiving TAU plus tDCS

    Time frame: 6 months

  6. Hamilton Anxiety Rating Scale (HAMA)

    To evaluate tDCS clinical effectiveness as the difference in anxiety symptom severity at end of the 6 month follow-up period between two treatment arms: those receiving treatment as usual (TAU) alone and those receiving TAU plus tDCS

    Time frame: 6 months

  7. Montgomery-Åsberg Depression Rating Scale-Self Report (MADRS-S)

    To evaluate tDCS clinical effectiveness as the difference in depressive symptom severity at end of the 6 month follow-up period between two treatment arms: those receiving treatment as usual (TAU) alone and those receiving TAU plus tDCS

    Time frame: 6 months

  8. Montgomery-Åsberg Depression Rating Scale (MADRS) clinical response

    To evaluate treatment response at the 10-week end of treatment period between treatment arms. Treatment response is defined as an improvement of 50% or more from baseline MADRS score.

    Time frame: 10 weeks

  9. Montgomery-Åsberg Depression Rating Scale (MADRS) treatment remission

    To evaluate treatment remission at the 10-week end of treatment period between treatment arms. Treatment remission is defined as a MADRS score of 10 or less.

    Time frame: 10 weeks

  10. Montgomery-Åsberg Depression Rating Scale (MADRS) clinical response

    To evaluate treatment response at the 6 month end of follow-up period between treatment arms. Treatment response is defined as an improvement of 50% or more from baseline MADRS score.

    Time frame: 6 months

  11. Montgomery-Åsberg Depression Rating Scale (MADRS) treatment remission

    To evaluate treatment remission at the 6 month follow-up period between treatment arms. Treatment remission is defined as a MADRS score of 10 or less.

    Time frame: 6 months

07

Study locations

1 of 6 sites recruiting
  • Cardiff and Vale Health Board
    Cardiff, CF24 4HQ, United Kingdom
    Not yet recruiting
    • Neil Harrison · Principal investigator
  • South London and Maudsley NHS Foundation Trust
    London, SE5 8AF, United Kingdom
    Recruiting
    • Cynthia Fu, MD, MSc, PhD · Principal investigator
  • Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust
    Newcastle, NE4 5PL, United Kingdom
    Not yet recruiting
    • Stuart Watson · Principal investigator
  • Northamptonshire Healthcare NHS Foundation Trust
    Northampton, NN5 6UD, United Kingdom
    Not yet recruiting
    • Chris Griffiths · Principal investigator
  • Nottinghamshire Healthcare NHS Foundation Trust
    Nottingham, NG7 2UH, United Kingdom
    Not yet recruiting
    • Sudheer Lankappa · Principal investigator
  • Hampshire and Isle of Wight Healthcare NHS Foundation Trust
    Southampton, SO14 3DT, United Kingdom
    Not yet recruiting
    • David Baldwin · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymised data will be made available on request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: a maximum of 1 year after publication of study results

Access criteria: Individual access by request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2027, 17 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 17 months is below that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 14, 2025
StartActual
Nov 18, 2025
Primary completionEst.
May 15, 2027
CompletionEst.
Dec 31, 2027
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07228468
Collaborators
Nottinghamshire Healthcare NHS Trust, Cardiff and Vale University Health Board, Northumberland, Tyne and Wear NHS Foundation Trust, Northamptonshire Healthcare NHS Foundation Trust, South London and Maudsley NHS Foundation Trust, Southern Health NHS Foundation Trust
Responsible party
Sponsor
First posted
Nov 14, 2025
Start date
Nov 18, 2025
Primary completion
May 15, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 26, 2026

Study contacts

Cynthia Fu
Contact
cynthia.fu@kcl.ac.uk
020 7848 0002
Cynthia Fu, MD, PhD
principal investigator · King's College London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion